Early diagnosis of melanoma remains extremely challenging. Currently there are no validated blood-based biomarkers for early diagnosis. Therefore, a reliable screening test is an unmet medical need. Autoantibodies are emerging as promising biomarkers for early cancer detection. In a proof of principle experiment we identified five autoantibodies that provide 95% sensitivity / specificity. Now we will confirm and validate our findings and develop a clinical test for melanoma diagnosis.
Molecular Characterisation Of Early Precursor Lesions Of A Novel Ñserrated Pathwayî Of Colorectal Cancer Using Gene Expression And Proteomics.
Funder
National Health and Medical Research Council
Funding Amount
$318,338.00
Summary
In Australia, CRC is the second highest cause of all cancer-related deaths. If detected early, CRC has a high success rate of cure, but a percentage of precursor lesions escape detection and show aggressive clinical behaviour to progress to CRC. These are difficult to diagnosis with existing technologies. We aim to understand the biology behind sessile serrated adenoma pathways and hence enhance early detection, diagnosis and treatments strategies.
Breast cancer is the most common cancer diagnosed in Australian women, affecting one in 8. While physical examination, mammography and ultrasound remain first-line screening tools, there are no reliable blood tests to aid diagnosis. This project aims to discover proteins in breast cancer tissue, or in the bloodstream of patients, which can be measured to provide information about the presence and severity of breast cancer. A new, reliable diagnostic test could benefit millions of women.
Quantitative Proteomic Analysis Of Faecal Biomarkers For Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$562,398.00
Summary
We have identified a number of potential biomarkers present in the stools of patients with colorectal cancer (CRC). We will use quantitative mass spectrometric techniques that we have developed to validate these biomarkers on a large number of faecal samples from patients with CRC and multiple control groups. We believe these studies will lead to a new panel of biomarkers which will improve the detection of early forms of colon cancer, thus reducing death from this disease.